SCHEMBL22845220

SCHEMBL22845220

CC(C)(C)OC(=O)N1CCc2c(n3ncc(Cc4ccc(OC(F)(F)F)cc4)c3[nH]c2=O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABHD6 Q9BV23 2/20 0.39
DAGLA Q9Y4D2 1/20 0.39
LIPE Q05469 1/20 0.38
P2RX3 P56373 2/20 0.37
KCNH2 Q12809 2/20 0.37
SCN5A Q14524 2/20 0.37
SCN9A Q15858 2/20 0.37
F12 P00748 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
ENPP2 Q13822 1/20 0.35
ATXN2 Q99700 1/20 0.35
GCGR P47871 1/20 0.35
SPR P35270 1/20 0.35
P2RX7 Q99572 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PARP1 P09874 1/20 0.34
TNKS2 Q9H2K2 1/20 0.34
PARP2 Q9UGN5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24469807 0.88 P2RX3 (0.43) P2RX3F12SPRPARP1TNKS2
SCHEMBL22717415 0.86 GPR119 (0.42) P2RX3F12GPR119SPRPARP1
SCHEMBL29670401 0.83 NAMPT (0.40) P2RX3F12GPR119SPRPARP1
SCHEMBL24484074 0.83 NAMPT (0.40) P2RX3F12GPR119SPRPARP1
SCHEMBL22845225 0.81 MAPT (0.46) P2RX3KCNH2MAPTPOLBENPP2
SCHEMBL29670347 0.79 F12 (0.40) F12GPR119MAPTSPRKDM4E
SCHEMBL22845224 0.79 PLAT (0.42) MAPTPOLBGCGRTNKS2PLAT
SCHEMBL22845221 0.79 GCGR (0.40) LIPEP2RX3KCNH2SCN5ASCN9A
SCHEMBL24469870 0.73 PARP1 (0.37) ABHD6DAGLASPRPARP1
SCHEMBL24469848 0.72 P2RX3 (0.42) P2RX3F12PARP1TNKS2PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL ABHD6 2070/4885DAGLA 3326/4885LIPE 1092/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL ABHD6 2070/4885DAGLA 3326/4885LIPE 1092/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL ABHD6 2070/4885DAGLA 3326/4885LIPE 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.